JPH02191223A - Iron-supplying preparation - Google Patents

Iron-supplying preparation

Info

Publication number
JPH02191223A
JPH02191223A JP63306272A JP30627288A JPH02191223A JP H02191223 A JPH02191223 A JP H02191223A JP 63306272 A JP63306272 A JP 63306272A JP 30627288 A JP30627288 A JP 30627288A JP H02191223 A JPH02191223 A JP H02191223A
Authority
JP
Japan
Prior art keywords
iron
preparation
present
citrate
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP63306272A
Other languages
Japanese (ja)
Other versions
JPH0559090B2 (en
Inventor
Akihisa Takaichi
晶久 高市
Toshihiko Okamoto
俊彦 岡本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Priority to JP63306272A priority Critical patent/JPH02191223A/en
Priority to NL8902439A priority patent/NL194959C/en
Priority to GB8922219A priority patent/GB2223405B/en
Priority to SE8903232A priority patent/SE509650C2/en
Priority to CH2559/91A priority patent/CH680569A5/de
Priority to CH3602/89A priority patent/CH681138A5/de
Priority to FR898912919A priority patent/FR2640505B1/en
Priority to US07/417,111 priority patent/US5087442A/en
Priority to DE3933164A priority patent/DE3933164B4/en
Priority to DE3943807A priority patent/DE3943807B4/en
Priority to KR1019890014192A priority patent/KR0143232B1/en
Priority to FR909000352A priority patent/FR2640506B1/en
Priority to GB9005119A priority patent/GB2230699B/en
Priority to US07/540,532 priority patent/US5160728A/en
Publication of JPH02191223A publication Critical patent/JPH02191223A/en
Publication of JPH0559090B2 publication Critical patent/JPH0559090B2/ja
Priority to SE9803394A priority patent/SE519516C2/en
Priority to NL9900032A priority patent/NL195070C/en
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent

Abstract

PURPOSE:To provide an iron-supplying agent capable of being readily used as an iron-supplying food on anemia, etc., containing a specific amount of an iron-containing compound, Na2CO3 and/or NaHCO3 and a neutralizing agent as essential ingredients. CONSTITUTION:An iron-supplying agent contains an iron-containing compound (e.g. ammonium citrate, ferrous sodium citrate or iron citrate) containing 0.01-3.5wt.%, preferably 0.06-0.6wt.%, of the iron, 10-35wt.% of Na2CO3 and (or) NaHCO3 and 20-70wt.% of a neutralizing agent (e.g. L-tartaric acid, citric acid or fumaric acid) as essential ingredients. The Na2CO3 is used in an amount of especially 11-31%, preferably 22-26%, and the NaHCO3 is 10-35%, preferably 20-30%, and most preferably the NaHCO3 is alone used in an amount of 20-25%.

Description

【発明の詳細な説明】 星東上立五里匁１ 本発明は鉄補給用製剤、より詳しくは鉄分の生体への補
給を行ない得る新しい製剤に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a preparation for iron supplementation, and more particularly to a new preparation capable of supplementing iron to living bodies.

術とその間　１、 生体において鉄はヘモグロビンの構成要素として重要な
役割を有しており、通常正常人においては食物からその
必要量が摂取され、これは全消化管、特に小腸（主に十
二指腸）から２価の形で吸収され、粘膜細胞内で３価に
酸化され、血流中に入ってそのキャリアプロティンであ
るトランスフェリン（β１−グロブリン）と結合し、貯
蔵臓器である肝臓、膵臓、貴簡等に運ばれる。また上記
鉄の正常人の１日の***量は約０．５〜’＋ｍｏである
といわれており、この量が必要摂取量でもある。1. Iron plays an important role in living organisms as a component of hemoglobin, and normal people usually take in the required amount from food, which is distributed throughout the digestive tract, especially the small intestine (mainly the duodenum). It is absorbed in the divalent form from the bloodstream, oxidized to the trivalent form within the mucosal cells, enters the bloodstream, and binds to its carrier protein transferrin (β1-globulin), which is then transferred to the storage organs such as the liver, pancreas, and the kidneys. etc. Further, the daily excretion amount of iron in a normal person is said to be about 0.5 to +mo, and this amount is also the required intake amount.

しかしながら、一般に食物からの上記鉄の吸収率は数％
程度と低く、この吸収率の低さより、生体はしばはしば
鉄欠乏性貧血等の病理状態に陥る。However, the absorption rate of iron from food is generally only a few percent.
Due to this low absorption rate, living bodies often fall into pathological conditions such as iron deficiency anemia.

この鉄欠乏性貧血としては、例えば萎黄病、特発性低色
素性貧血、妊娠時の低色素性貧血、胃腸疾患における低
色素性貧血等が知られてお１す、現在之等の病理状態の
改善、即ち貧血の予防、治療を目的とした各種の鉄化合
物製剤（造血剤）が知られているが、公知の造血剤は、
その製剤形態での均−性、安定性、摂取や服用の容易性
（飲みヤすざ、味等）、充分な鉄分の安定補給性等にお
いて、尚改善されるべき余地がめる。Examples of iron deficiency anemia include chlorosis, idiopathic hypochromic anemia, hypochromic anemia during pregnancy, and hypochromic anemia associated with gastrointestinal diseases. Various iron compound preparations (hematopoietic agents) are known for the purpose of improving, that is, preventing and treating anemia.
There is still room for improvement in the uniformity and stability of the formulation, ease of ingestion and dosing (drinkability, taste, etc.), stable supply of sufficient iron content, etc.

明が解決しようとする口　１、 本発明の目的は、上記公知の鉄化合物製剤に代って、よ
り実用性が高く、殊に製剤形態での均一性、安定性に優
れており、摂取や服用が容易（飲みやすく、味等に優れ
ている）で、しかも充分な鉄分を安定して補給できる新
しい鉄補給用製剤を提供することにある。1. The purpose of the present invention is to provide a more practical alternative to the above-mentioned known iron compound preparations, which is particularly excellent in uniformity and stability in the form of a preparation, and which is easy to ingest and use. To provide a new iron supplementation preparation that is easy to take (easy to drink, has excellent taste, etc.) and can stably supply sufficient iron.

本発明者らは、上記目的より鋭意研究を重ねた結果、鉄
含有化合物の所定量と共に炭酸ナトリウム及び（又は）
炭酸水素ナトリウムと中和剤とを所定割合で必須成分と
して含有させた製剤が、上記目的に合致する新しい鉄補
給用製剤として有効であることを見出し、ここに本発明
を完成するに至った。As a result of intensive research for the above purpose, the present inventors discovered that sodium carbonate and/or
The present inventors have discovered that a preparation containing sodium bicarbonate and a neutralizing agent as essential components in a predetermined ratio is effective as a new iron supplement preparation that meets the above objectives, and has now completed the present invention.

問　１、を解決するための　段 本発明によれば鉄含有化合物を鉄として０．０１〜３．
５重量％と共に、炭酸ナトリウム及び（又は）炭酸水素
ナトリウム１０〜３５重量％と中和剤２０〜７０重量％
とを必須成分として含有する鉄補給用製剤、殊に鉄含有
化合物がクエン酸鉄アンモニウム、クエン酸第一鉄ナト
リウム及びクエン酸鉄から選択され、錠剤、顆粒剤又は
カプセル剤の形態を有する上記鉄補給用製剤が提供され
る。In order to solve Question 1, according to the present invention, the iron-containing compound is 0.01 to 3.
5% by weight, together with 10-35% by weight of sodium carbonate and/or sodium bicarbonate and 20-70% by weight of a neutralizing agent.
and, in particular, the iron-containing compound is selected from iron ammonium citrate, ferrous sodium citrate, and iron citrate, and the iron supplement is in the form of tablets, granules, or capsules. Supplemental formulations are provided.

本発明の鉄補給用製剤、殊に錠剤等の形態を有する本発
明製剤は、その製剤形態で保存安定性に優れており、且
つ溶解性、分散性も良好で、用時水中に投入するだけで
中和による炭酸ガスの発生を伴って、製剤中に含有され
る鉄含有化合物を水中に容易につ均一に溶解、分散させ
得、この溶液は服用（経口投与）が非常に容易且つ美味
しい特徴を有すると共に、該服用によって生体に充分な
鉄分を補給、吸収させることができる。従ってその利用
によれば、例えば貧血等の治癒効果が期待できる。The preparation for iron supplementation of the present invention, especially the preparation of the present invention in the form of a tablet, etc., has excellent storage stability in its form, and also has good solubility and dispersibility, so that it can be simply added to water at the time of use. With the generation of carbon dioxide gas through neutralization, the iron-containing compound contained in the preparation can be easily and uniformly dissolved and dispersed in water, and this solution is very easy and delicious to take (oral administration). In addition, by taking the drug, sufficient iron can be supplied and absorbed by the living body. Therefore, its use can be expected to have a therapeutic effect on, for example, anemia.

本発明製剤を構成する鉄含有化合物としては、例えばク
エン酸鉄アンモニウム、クエン酸第一鉄ナトリウム、ク
エン酸鉄、グルコン酸第一鉄、ピロリン酸第一鉄、ピロ
リン酸第二鉄、乳酸鉄、硫酸第一鉄、塩化第二鉄、三二
酸化鉄、鉄クロロフィンナトリウム、フマル酸第一鉄、
スレオニン鉄、オロチン酸第一鉄、含糖酸化鉄、グルコ
ン酸第二鉄等を例示でき、之等の内では特にクエン酸鉄
アンモニウム、クエン酸第一鉄ナトリウム及びクエン酸
鉄が好ましい。之等の鉄含有化合物はそれぞれ入手され
る形態、通常粒度が２００μｍ以下の粉末形態で本発明
に有利に利用できる。また之等は単独で本発明製剤に配
合されてもよく、２種以上を混合して配合されてもよい
。その配合量は鉄としてＯ，Ｏ’ｌ〜３．５％（重量％
、以下同じ）、好ましくは０．０６〜０．６％の範囲か
ら選択されるのがよく、この範囲内での配合によって、
本発明製剤に所期の優れた鉄補給効果をもたらす。Examples of iron-containing compounds constituting the preparation of the present invention include ammonium citrate, sodium ferrous citrate, iron citrate, ferrous gluconate, ferrous pyrophosphate, ferric pyrophosphate, iron lactate, Ferrous sulfate, ferric chloride, iron sesquioxide, sodium iron chlorophyne, ferrous fumarate,
Examples include iron threonine, ferrous orotate, sugar-containing iron oxide, and ferric gluconate, among which ammonium iron citrate, sodium ferrous citrate, and iron citrate are particularly preferred. These iron-containing compounds can be advantageously utilized in the present invention in the form in which they are obtained, usually in powder form with a particle size of 200 μm or less. Further, these may be blended alone in the preparation of the present invention, or two or more of them may be blended. The blending amount is O, O'l ~ 3.5% (wt%) as iron.
, hereinafter the same), preferably from the range of 0.06 to 0.6%, and by blending within this range,
The preparation of the present invention provides the expected excellent iron supplementation effect.

特に好ましい上−２鉄含有化合物の配合量としては、ク
エン酸鉄アンモニウムでは０．６〜１．８％、クエン酸
第一鉄ナトリウムでは０．６〜３．０％、クエン酸鉄で
は０．４〜１６８％とするのがよい。Particularly preferred amounts of di-ferrous compounds are 0.6 to 1.8% for ammonium iron citrate, 0.6 to 3.0% for sodium ferrous citrate, and 0.6 to 1.8% for iron citrate. It is preferable to set it to 4 to 168%.

本発明製剤は上記鉄含有化合物と共に、炭酸ナトリウム
及び（又は）炭酸水素ナトリウムと中和剤との所定量を
発泡成分として配合することを必須とする。ここで用い
られる中和剤とは、上記炭酸ナトリウム及び炭酸水素ナ
トリウムを中和させて炭酸ガスを発生させ得る酸性化合
物をいう。該化合物には、例えば代表的にはＬ−酒石酸
、クエン酸、フマル酸、アスコルビン酸等の有機酸が包
含される。The formulation of the present invention requires that a predetermined amount of sodium carbonate and/or sodium bicarbonate and a neutralizing agent be blended together with the above-mentioned iron-containing compound as foaming ingredients. The neutralizing agent used here refers to an acidic compound capable of neutralizing the above-mentioned sodium carbonate and sodium hydrogen carbonate to generate carbon dioxide gas. Such compounds typically include organic acids such as L-tartaric acid, citric acid, fumaric acid, and ascorbic acid.

上記発泡成分の本発明製剤中への配合割合は、得られる
本発明製剤を水に溶解ざぜた場合に、溶液が酸性、特に
ｐＨ約３．５〜４．６程度の酸性を呈するものとなる割
合とするのがよ。より具体的には上記割合は炭酸ナトリ
ウム及び（又は）炭酸水素ナトリウム１０〜３５％及び
中和剤２０〜７０％の範囲から選択されるのがよい。特
に炭酸ナトリウムは１１〜３１％、好ましくは２２〜２
６％、炭酸水素ナトリウムは１０〜３５％、好ましくは
２０〜３０％の範囲から選ばれるのがよく、その内でも
炭酸水素ナトリウムを単独で２０〜２５％の範囲で用い
るのが最も好ましい。また中和剤は、２０〜７０％、好
ましくは３０〜４０％の範囲から選択され、特にＬ−酒
石酸を２０〜２５％及びアスコルビン酸を８〜１５％の
範囲内で使用するのが最も好ましい。上記発泡成分の配
合により本発明所期の優れた効果が達成される。The blending ratio of the foaming component in the formulation of the present invention is such that when the resulting formulation of the present invention is dissolved in water, the solution exhibits acidity, particularly acidity with a pH of about 3.5 to 4.6. It's best to use it as a percentage. More specifically, the above proportions are preferably selected from the range of 10-35% of sodium carbonate and/or sodium bicarbonate and 20-70% of the neutralizing agent. In particular, sodium carbonate is 11 to 31%, preferably 22 to 2%.
6%, sodium hydrogen carbonate is preferably selected from the range of 10 to 35%, preferably 20 to 30%, and among these, it is most preferable to use sodium hydrogen carbonate alone in the range of 20 to 25%. The neutralizing agent is selected from the range of 20 to 70%, preferably 30 to 40%, and most preferably L-tartaric acid is used in the range of 20 to 25% and ascorbic acid is used in the range of 8 to 15%. . By blending the above-mentioned foaming components, the excellent effects desired by the present invention can be achieved.

また、本発明製剤は、上記鉄含有化合物及び発泡成分を
必須成分として、他に通常知られている各種の添加剤成
分、例えば賦形剤、結合剤、崩壊剤、滑沢剤、増粘剤、
表面活性剤、浸透圧調節剤、電解質、甘味料、香料、色
素、ｐ目調節剤等を必要に応じて適宜添加配合すること
ができる。上記添加剤としては、例えば小麦澱粉、馬鈴
薯澱粉、コーンスターチ、デキストリン等の澱粉類、シ
ョ糖、ブドウ糖、果糖、麦芽糖、キシロース、乳糖等の
糖類、ソルビトール、マンニトール、マルチトール、キ
シリトール等の糖アルコール類、カップリングシュガー
、パラチノース等の糖転位配糖体、リン酸カルシウム、
硫酸カルシウム等の賦形剤、澱粉、糖類、ゼラチン、ア
ラビアガム、デキストリン、メチルチセルロース、ポリ
ビニルピロリドン、ポリビニルアルコール、ヒドロキシ
プロピルセルロース、キサンタンガム、ペクチン、トラ
ガントガム、カゼイン、アルギン酸等の結合剤乃至増粘
剤、ロイシン、イソロイシン、Ｌ−バリン、シュガーエ
ステル、硬化油、ステアリン酸、ステアリン酸マグネシ
ウム、タルク、マクロゴール等の滑沢剤、アビセル、Ｃ
ＭＣ，ＣＭＣ−Ｎａ。In addition, the preparation of the present invention contains the above iron-containing compound and foaming component as essential components, and various other commonly known additive components, such as excipients, binders, disintegrants, lubricants, and thickeners. ,
Surfactants, osmotic pressure regulators, electrolytes, sweeteners, fragrances, pigments, p-eye regulators, and the like can be added and blended as appropriate. Examples of the above additives include starches such as wheat starch, potato starch, corn starch, and dextrin; sugars such as sucrose, glucose, fructose, maltose, xylose, and lactose; and sugar alcohols such as sorbitol, mannitol, maltitol, and xylitol. , coupling sugar, sugar transfer glycosides such as palatinose, calcium phosphate,
Excipients such as calcium sulfate, binders and thickeners such as starch, sugars, gelatin, gum arabic, dextrin, methylthicellulose, polyvinylpyrrolidone, polyvinyl alcohol, hydroxypropylcellulose, xanthan gum, pectin, gum tragacanth, casein, alginic acid, etc. , leucine, isoleucine, L-valine, sugar ester, hydrogenated oil, stearic acid, magnesium stearate, talc, lubricant such as macrogol, Avicel, C
MC, CMC-Na.

ＣＭＣ−〇ａ等の崩壊剤、ポリソルベート、レシチン等
の表面活性剤、糖類、糖アルコール類、アスパラテーム
、アリテーム等のジペプチド、その他ステビア、サッカ
リン等の甘味料等を例示でき、之等は必須成分との関係
や製剤の性質、製造法等を考慮してその適当量を適宜選
択して用いることができる。Examples include disintegrants such as CMC-○a, surfactants such as polysorbate and lecithin, sugars, sugar alcohols, dipeptides such as aspartame and alitame, and other sweeteners such as stevia and saccharin, which are essential ingredients. An appropriate amount can be appropriately selected and used in consideration of the relationship with the drug, the properties of the preparation, the manufacturing method, etc.

更に、本発明製剤にはビタミン類、特にジアノコバラミ
ンやアスコルビン酸（ビタミンＣ）等の適当量を添加配
合することができ、上記ビタミンＣは抗酸化剤として機
能する他、必須成分とする鉄含有化合物の生体への吸収
性を一層高めて、本発明製剤の鉄補給効果を助長でき、
更に本発明製剤によるビタミン類の補給をも可能とする
。上記ビタミン類の配合割合は、特に限定はないが、通
常ビタミンＣでは３０％までの量、好ましくは約５〜２
５％の範囲から選ばれるのが好ましい。Furthermore, appropriate amounts of vitamins, particularly dianocobalamin and ascorbic acid (vitamin C), can be added to the preparation of the present invention, and the vitamin C functions as an antioxidant and also contains iron, which is an essential component. It is possible to further enhance the absorbability of the contained compounds into the living body and promote the iron replenishment effect of the preparation of the present invention,
Furthermore, it is also possible to supplement vitamins with the preparation of the present invention. The blending ratio of the above vitamins is not particularly limited, but the amount of vitamin C is usually up to 30%, preferably about 5 to 2%.
It is preferably selected from a range of 5%.

本発明製剤の製造法は、基本的には通常のこの種製剤、
例えば発泡錠剤の製造法と同様のものとすることができ
る。即ち、発泡錠剤形態の本発明製剤は、所定量の各成
分を秤量、混合し、直接粉末圧縮法、乾式又は湿式顆粒
圧縮法等に従って実施できる。The method for producing the preparation of the present invention is basically a conventional preparation of this kind,
For example, it can be similar to the method for manufacturing effervescent tablets. That is, the preparation of the present invention in the form of an effervescent tablet can be prepared by weighing and mixing predetermined amounts of each component, and then performing direct powder compression, dry or wet granule compression, or the like.

かくして得られる本発明製剤（発泡錠剤等）は、これを
水中に投入するだけで、経口投与に適した飲料形態とな
り、これは経口投与される。The preparation of the present invention (effervescent tablet, etc.) thus obtained becomes a drink form suitable for oral administration simply by adding it to water, and is administered orally.

その投与量は、これを適用すべき生体の年齢、性別、体
重や疾患の程度等に応じて適宜決定され、特に限定され
るものではないが、一般には１錠約１．５〜６．０ＣＩ
に調製された本発明錠剤の１〜２錠剤を１回に水１００
〜３００ｍＧに溶かして服用させればよい。The dosage is appropriately determined depending on the age, sex, weight, degree of disease, etc. of the organism to which it is applied, and is not particularly limited, but generally one tablet is approximately 1.5 to 6.0 CI.
1 to 2 tablets of the present invention prepared in 100 g of water at a time.
It may be dissolved in ~300mG and administered.

本発明製剤は、特に上述した発泡錠剤に限定されるもの
ではなく、前記組成範囲を有する限り、水に溶解、分散
させて服用される適宜の形態、例えば顆粒剤、散剤、カ
プセル剤等の形態であってもよく、更にかかる水に溶解
、分散させて服用される形態に限らず、例えば水溶液等
の液状形態であってもよい。The preparation of the present invention is not particularly limited to the above-mentioned effervescent tablets, but may be in any suitable form, such as granules, powders, capsules, etc., which can be dissolved or dispersed in water and taken. Furthermore, it is not limited to the form in which the drug is taken by dissolving or dispersing it in water, but may be in a liquid form such as an aqueous solution.

本発明製剤の特に好ましい配合組成の具体例としては以
下のもの（単位二重量％）を例示できる。As specific examples of particularly preferable compositions of the formulation of the present invention, the following (unit: double weight %) can be exemplified.

クエン酸鉄アンモニウム、クエン 酸第一鉄ナトリウム及びクエン＠　　０．６〜１．５％
鉄から選ばれる鉄含有化合物 炭酸水素ナトリウム　　　　　　　２０　〜２５　　％
Ｌ−酒石酸等の有機酸系中和剤・　２０　〜２５　　％
アスコルビン！！　　　　　　　　　　８〜１５　　％
及−旦−五−ヱー１ 本発明によれば、新しい鉄補給用製剤が提供される。該
製剤は安定であり、保存性に優れており、しかも溶けや
すく、服用も容易である利点があり、その服用によって
充分な鉄分を安全に生体に供給、吸収させることができ
、貧血治療等の効果を奏し得、また低カロリーである特
徴も有している。更に、本発明製剤は総じて味がよく、
鉄の味をマスクして清涼感のあるおだやかな味を有する
特徴がある。Ammonium ferrous citrate, sodium ferrous citrate and citric acid @ 0.6-1.5%
Iron-containing compound selected from iron Sodium hydrogen carbonate 20-25%
Organic acid neutralizing agent such as L-tartaric acid・20 to 25%
Ascorbine! ! 8-15%
A-D-5-E-1 According to the present invention, a new iron supplementation formulation is provided. This preparation is stable, has excellent storage stability, and has the advantage of being easily soluble and easy to take. By taking it, sufficient iron can be safely supplied and absorbed by the body, and it can be used for anemia treatment, etc. It is effective and also has the characteristic of being low in calories. Furthermore, the preparation of the present invention has good taste overall;
It has a characteristic that it masks the taste of iron and has a refreshing and mild taste.

！−−１−−１ 以下、本発明を更に詳しく説明するため実施例を挙げる
。尚、各例中部及び％は特記しない限り重量部及び重量
％を示す。! --1--1 Examples will be given below to explain the present invention in more detail. Incidentally, in each example, parts and percentages indicate parts by weight and percentages by weight unless otherwise specified.

実施例　１〜１８ 下記第１表に示す組成となる各成分を混合し、混合物を
直接粉末圧縮法により製錠して本発明製剤（発泡錠剤）
を調製した。Examples 1 to 18 The ingredients having the composition shown in Table 1 below are mixed, and the mixture is directly made into tablets by powder compression method to obtain the preparation of the present invention (expandable tablet).
was prepared.

上記で得られた本発明製剤（実施例１〜１８の発泡錠剤
）は、鉄の補給食品として、美味（清涼感等）を有して
おり、手軽に鉄の補給が可能な新しい食品として有効で
ある。また之等の製剤は、乾燥状態で提供されるもので
あり、水溶液状態と比べて、内容物の安定性に優れてお
り、味及び栄養効果の点でも優れたものである。更に之
等の製剤はこれを水中に投入すると速やかに溶解、分散
し、溶液が総じて透明となり、この溶解後の液性より呈
色等による不快感もなく、また色素等を添加された本発
明製剤は、その飲用時の液の色を任意に調節されており
、その外観も好ましいものである。加えて、上記本発明
製剤は軽量で安定性に富んでおり、運搬等にも便利であ
り、市場流通に好ましい製品である。The above-obtained preparations of the present invention (the effervescent tablets of Examples 1 to 18) have a delicious taste (cooling sensation, etc.) as an iron supplement food, and are effective as a new food that can easily supplement iron. It is. In addition, these preparations are provided in a dry state, and are superior in terms of stability of contents and taste and nutritional effects compared to aqueous solutions. Furthermore, when these preparations are put into water, they are quickly dissolved and dispersed, and the solution becomes generally transparent, and the liquid properties after dissolution do not cause discomfort due to coloration, and the present invention, which has added pigments, etc. The color of the liquid when drinking the preparation is arbitrarily controlled, and its appearance is also desirable. In addition, the above-mentioned formulation of the present invention is lightweight, highly stable, and convenient for transportation, making it a product preferred for market distribution.

特に鉄化合物としてクエン酸鉄アンモニウムを使用した
本発明製剤（実施例１〜７．１０〜１８）は、鉄の溶解
性がより一層優れており、充分な看の鉄を容易に補給さ
せることができる。In particular, the preparations of the present invention (Examples 1 to 7 and 10 to 18) using iron ammonium citrate as the iron compound have even better iron solubility and can easily supply sufficient iron. can.

また、実施例１に記載の本発明製剤は、殊に惨めで味が
よく、鉄の味をマスクして、清涼感のあるおだやかな味
を有するものであった。Furthermore, the preparation of the present invention described in Example 1 had a particularly pleasant taste, masked the iron taste, and had a refreshing and mild taste.

（以　上）(that's all)

Claims (2)

【特許請求の範囲】[Claims] （１）鉄含有化合物を鉄として０．０１〜３．５重量％
と共に、炭酸ナトリウム及び（又は）炭酸水素ナトリウ
ム１０〜３５重量％と中和剤２０〜７０重量％とを必須
成分として含有することを特徴とする鉄補給用製剤。(1) 0.01 to 3.5% by weight of iron-containing compound as iron
An iron supplement preparation characterized by containing 10 to 35% by weight of sodium carbonate and/or sodium bicarbonate and 20 to 70% by weight of a neutralizing agent as essential components. （２）鉄含有化合物がクエン酸鉄アンモニウム、クエン
酸第一鉄ナトリウム及びクエン酸鉄から選択され、錠剤
、顆粒剤又はカプセル剤の形態を有する請求項１記載の
製剤。2. A formulation according to claim 1, wherein the iron-containing compound is selected from ferrous ammonium citrate, ferrous sodium citrate and iron citrate, and is in the form of tablets, granules or capsules.
JP63306272A 1988-10-04 1988-12-02 Iron-supplying preparation Granted JPH02191223A (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
JP63306272A JPH02191223A (en) 1988-10-04 1988-12-02 Iron-supplying preparation
NL8902439A NL194959C (en) 1988-10-04 1989-10-02 Preparation for administering iron.
GB8922219A GB2223405B (en) 1988-10-04 1989-10-03 Effervescent iron preparation
SE8903232A SE509650C2 (en) 1988-10-04 1989-10-03 Iron supply compositions comprising an iron-containing compound, an alkali metal carbonate and / or alkali metal hydrogen carbonate and a neutralizing agent
CH2559/91A CH680569A5 (en) 1988-10-04 1989-10-03
CH3602/89A CH681138A5 (en) 1988-10-04 1989-10-03
FR898912919A FR2640505B1 (en) 1988-10-04 1989-10-03 PREPARATION FOR THE SUPPLY OF IRON, PREPARATION FOR THE SUPPLY OF VITAMINS AND METHOD FOR STABILIZING AN EFFERVESCENT PREPARATION
DE3943807A DE3943807B4 (en) 1988-10-04 1989-10-04 Effervescent vitamin or iron compsn. - contg. sodium carbonate or sodium bi:carbonate, neutralising agent and potassium carbonate as stabilising agent
DE3933164A DE3933164B4 (en) 1988-10-04 1989-10-04 Prepn. for iron supply - comprises specified amts. of specified iron contg. cpd., sodium carbonate or bi:carbonate and a neutralising agent
US07/417,111 US5087442A (en) 1988-10-04 1989-10-04 Preparation for iron supply, preparation for vitamin supply and method for stabilizing a foam preparation
KR1019890014192A KR0143232B1 (en) 1988-10-04 1989-10-04 Preparation for iron supply, preparation for vitamin supply and method for stabilizing a foam preparation
FR909000352A FR2640506B1 (en) 1988-10-04 1990-01-12 PREPARATION FOR THE SUPPLY OF IRON, PREPARATION FOR THE SUPPLY OF VITAMINS AND METHOD FOR STABILIZING AN EFFERVESCENT PREPARATION
GB9005119A GB2230699B (en) 1988-10-04 1990-03-07 Preparation for vitamin supply and method for stabilising a foam preparation
US07/540,532 US5160728A (en) 1988-10-04 1990-06-19 Preparation for iron supply, preparation for vitamin supply and method for stabilizing a foam preparation
SE9803394A SE519516C2 (en) 1988-10-04 1998-10-06 Foam preparation and method of stabilizing a foam preparation
NL9900032A NL195070C (en) 1988-10-04 2003-04-03 Preparation for administering vitamins.

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP25066388 1988-10-04
JP63-250663 1988-10-04
JP63306272A JPH02191223A (en) 1988-10-04 1988-12-02 Iron-supplying preparation

Publications (2)

Publication Number Publication Date
JPH02191223A true JPH02191223A (en) 1990-07-27
JPH0559090B2 JPH0559090B2 (en) 1993-08-30

Family

ID=17211197

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63306272A Granted JPH02191223A (en) 1988-10-04 1988-12-02 Iron-supplying preparation

Country Status (2)

Country Link
JP (1) JPH02191223A (en)
KR (1) KR0143232B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002080347A (en) * 2000-09-04 2002-03-19 Taisho Pharmaceut Co Ltd Oral liquid medicine formulated with iron compound

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
MXPA05004278A (en) 2002-10-25 2005-10-05 Foamix Ltd Cosmetic and pharmaceutical foam.
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
CA2760186C (en) 2009-04-28 2019-10-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011039638A2 (en) 2009-10-02 2011-04-07 Foamix Ltd. Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002080347A (en) * 2000-09-04 2002-03-19 Taisho Pharmaceut Co Ltd Oral liquid medicine formulated with iron compound

Also Published As

Publication number Publication date
KR900005963A (en) 1990-05-07
KR0143232B1 (en) 1998-07-15
JPH0559090B2 (en) 1993-08-30

Similar Documents

Publication Publication Date Title
US8182850B2 (en) Mixture of iron and copper salts masking metallic taste
JP3224767B2 (en) Oral zinc composition
JPH02191223A (en) Iron-supplying preparation
EP2073821B1 (en) Mixture of iron and copper salts masking metallic taste
JPH08208490A (en) Improved calcium meal auxiliary composition
CA2281054C (en) Combination of zinc ions and vitamin c and method of making
US5160728A (en) Preparation for iron supply, preparation for vitamin supply and method for stabilizing a foam preparation
US5424074A (en) Pharmaceutical composition for potassium supplementation
US20040048925A1 (en) Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
JPH114666A (en) Foaming agent composition for supplying magnesium
US20040220266A1 (en) Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
JP2617810B2 (en) Potassium supplement foam
JP2818892B2 (en) Foam formulation
WO2019119445A1 (en) Nadh compound, and formulation and application thereof
JP2720165B2 (en) Glucose electrolyte compounding agent
WO2005096846A1 (en) Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
KR20200083971A (en) Calcium supplement composition
JPH0390030A (en) Calcium preparation
JPH09157174A (en) Calcium preparation
MXPA97007902A (en) Zinc compositions that keep every aromapera oral use that incorporates co

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080830

Year of fee payment: 15

LAPS Cancellation because of no payment of annual fees